Three year post heart transplant outcomes of desensitized durable mechanical circulatory support patients

J Heart Lung Transplant. 2023 Oct;42(10):1408-1414. doi: 10.1016/j.healun.2023.05.001. Epub 2023 May 6.

Abstract

Background: The risks and benefits of desensitization therapy (DST) in highly sensitized mechanical circulatory support (MCS) patients are not well known. We investigated 3 year post-transplant outcomes of desensitized durable MCS patients.

Methods: Among 689 consecutively enrolled heart transplantation recipients between 2010 and 2016, we categorized them into Group A (desensitized MCS patients, n = 21), Group B (desensitized non-MCS patients, n = 28) and Group C (all nondesensitized patients, n = 640). Post-transplant outcomes included the incidence of primary graft dysfunction, 3-year survival, freedom from cardiac allograft vasculopathy, nonfatal major adverse cardiac events, any treated rejection, acute cellular rejection, antibody mediated rejection (AMR) and infectious complications.

Results: The types of DST in Groups A and B were similar and included combinations of rituximab/intravenous immunoglobulin and plasmapheresis/bortezomib. Group A, compared with Group B, showed significantly higher pre-DST panel reactive antibody (PRA) (92.2 ± 9.8 vs. 83.3 ± 15.6, P = 0.007) and higher PRA reduction after DST (-22.2 ± 26.9 vs. -6.3 ± 7.5, P = 0.015). Groups A and C showed comparable primary graft dysfunction, 3-year survival, freedom from cardiac allograft vasculopathy, nonfatal major adverse cardiac events, any treated rejection, acute cellular rejection, and AMR. Although statistically not significant, Group A showed numerically higher 3-year freedom from AMR than Group B. Infectious complications were similar in both Groups A and B.

Conclusions: DST for MCS patients showed significant PRA reduction, resulting in an expansion of the donor pool. The post-transplant outcome of desensitized MCS patients showed comparable clinical outcomes to non-desensitized control patients in the same study period, revealing the safety and efficacy of DST.

Keywords: desensitization therapy; heart transplantation; infection; mechanical circulatory support; prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies
  • Graft Rejection
  • Graft Survival
  • Heart Transplantation*
  • Humans
  • Kidney Transplantation* / adverse effects
  • Primary Graft Dysfunction* / etiology
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Antibodies